Drug Quality Concerns Rise as NSQ Cases Double in Tripura

• By Thetripurapost Desk, Agartala
• Mar 17, 2026
• 946

The incidence of substandard, or “Not of Standard Quality” (NSQ), drugs in Tripura has nearly doubled over the past year, raising serious public health concerns. During the 2025–26 fiscal year, a total of 43 such drugs were identified, compared to 19 in 2024–25. The data was disclosed by the Chief Minister in response to a query raised by the opposition Congress during the विधानसभा session.
Reaffirming the government’s stance, the Chief Minister emphasized that there will be no compromise on pharmaceutical quality. He noted that stringent surveillance mechanisms—comprising routine sampling, laboratory testing, and systematic audits—are actively in place to detect and curb irregularities.
Out of the 43 identified cases, decisive regulatory action has been initiated in 16 instances against the respective manufacturing entities. These measures include suspension of production and cancellation of licenses. Additionally, three cases are currently sub judice, while investigations into the remaining cases are ongoing.
Public health experts caution that the circulation of substandard drugs poses a grave risk to patient safety and can significantly erode trust in the healthcare system. The rising trend is therefore being interpreted as a critical warning signal for the state’s healthcare infrastructure.
In conclusion, the surge in NSQ drugs underscores the urgent need for coordinated intervention. Experts advocate for a multi-stakeholder approach involving regulatory authorities, pharmaceutical manufacturers, and healthcare providers to ensure robust quality assurance and safeguard public health.